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els. The precise mechanism of these effects is unknown, but may be related
to the inhibition of platelet function and/or leukocyte recruitment.
Robert J. Anders, John C. Alexander, Gary L. Hantsbarger, Dan M. Burns, Stuart
D. Oliver, Graham Cole, Desmond J. Fitzgerald. Searle Pharm., Skokie, IL; Besse/aar
Associates, Leeds, UK; Royal College of Surgeon, Dublin, Ireland
1931-1111 Platelet Activation and Aggregation by
Therapeutic Doses of Heparin
1931-1131 Demonstration of Potent Inhibition of Platelet
Aggregation with an Orally Active GPllb/IIIA
Receptor Antagonist
Zihui Xiao, Pierre Theroux, John R. Plachetka. Montreal Heart Institute, Montreal,
Quebec, Canada
Thus, heparin, but not argatroban, a direct thrombin inhibitor, induced P-
selectin expression and GP lib/lila activation in the basal state and following
agonist stimulation at low concentrations.
Control
Basal 1.80 ± 0.67 0.66 ± 0.114 0.011 ± 0.0024
ADP 701 ± 15.99 3.5 ± 1,48 101 ± 4.13 018±0074 43 ± 2.25
TRP 18.8 ± 16,45 081 ± 0.61 2.77 ± 2.02 0.05 ± 0.039 2.2 ± 1.84
Heparin
Basal 3.60 ± 1,42* 1.00 ± 0.292* 0.018 ± 0.0047 t
ADP 76.6 ± 12,49* 4.2 ± 1.70* 13.2 ± 4,43* 0.24 ± 0.087* 88 ± 3.06t
TRP 32.9 ± 25.60* 1.5 ± 1.17* 3.32 ± 2.24* 0.06 ± 0.039 6.2 ± 1.84*
D, x =PBO
10 all others=50 mg dose
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This single-blind, placebo-controlled study evaluated the tolerability and
pharmacodynamic (PO) response of the first dose of the oral GPlib/llia re-
ceptor antagonist, SC-54684A (ethyl 3S-[[4-[[4(amino-iminomethyl)phenyl]a-
mino]-l,4-dioxobutyl]amino]-4-pentynoate, monohydrochloride). SC-54684A
(SC) is the pro-drug of the active compound, SC-54701A. Six healthy male
subjects received 50 mg of SC (free base) and 2 received placebo (PBO). Re-
sults of the inhibition to AOP (20 I'M) induced platelet aggregation are shown
below:
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Effects of Inhibition of Nitric Oxide Synthesis in
Proximal and Distal Segments in Patients with
Normal Arteries and in Patients with Coronary
Artery Disease
Dimltris Tousoulis, Tom Crake, Costas Tentolouris, David C. Lefroy, John Gialafos,
Pavlos Toutouzas, Graham Davies. Cardiology Units, Athens University Medical
School, Greece; Hammersmith Hospital, London. UK
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Bleeding time increased a mean of 5.6 fold at 4 hrs post-dose and returned
to within normal limits at 8 hrs after dosing. No significant changes in lab
values or bleeding complications occurred. Peak serum concentrations co-
incided with peak PO effects of inhibition of platelet aggregation.
Conclusion; SC-54684A has a rapid onset of potent inhibition of platelet
aggregation that is sustained for up to 10 hours after dosing.
1931-11412.3 ± 2.07*2.0 ± 2.61
Max%BIPL%BI
2.30 ± 0.75 0.82 ± 0.192* 0.015 ± 00041*
691 ± 1962 3.5± 1.75 11.4±4,42 0.21 ±0.085
21.0 ± 14.23 0.88 ± 0.56 2.48 ± 1.12 0.05 ± 0.021
PAC-1
PL%
*p < 0.05 and t p < 001 vs Control
Argatroban
Basal
ADP
TRP
To understand better the complex interaction of heparin with platelets,
this study investigated platelet function by flow cytometry and aggregation
curves, with and without the drug, in 7 pts with unstable angina and 7 normal
individuals. Method and Results: Platelet aggregation induced by low doses
AOP (0.3125 /LM) and thrombin receptor agonist peptide (TRAP 0.625 I'M)
was quantified in platelet-rich plasma (PRP) before and after the administra-
tion of intravenous heparin at doses prolonging the aPTI 2.5 x control and
also after the addition in whole blood, ex vivo of therapeutic concentration of
heparin (0.2 U/mlj, argatroban (1 ng/ml) or of an equal volume of normal saline
(Control). Platelet activation was evaluated by the percentage of fluorescein
positive platelets (PL%) and the binding index per platelet (BI), using antibod-
ies directed against P-selectin (C062) and activated GP lib/lila receptor (pAC-
1). Following intravenous heparin, the maximal shift in platelet aggregation
(Max%) increased from 6.3 ± 3.6 to 11.6 ± 8.5 with AOP and from 4.4 ± 3.0
to 11.9 ± 5.2 (p < 0.05) with TRAP. The results of the ex vivo studies (x ± SO)
were:
PRP optical aggregation (%) Before AfterASA
1 h. 24 h
ADP (5/LM): L-ASA 73 ± 21 50 ± 14* 45± 15*
H-ASA 65 ± 23 54 ± 17* 52 ± 16*
PI 69 ± 18 72 ± 22 69 ± 14
Col (3 /Lg/ml): L-ASA 64 ± 19 33 ± 13* 36 ± 18*
H-ASA 60± 16 32 ± 17* 34 ± 14*
PI 55 ± 13 56 ± 18 57 ± 14
Rosa-Maria Lid6n, David Garcia-Dorado, Jaume Figueras, Juan Oliveras,
Anna Angles, Jasone Monasterio, J. Soler-Soler, Pierre Theroux. Hospital Vall
d'Hebron, Barcelona, Spain; Montreal Heart Institute, Montreal, Canada
Prompt inhibition of platelet aggregation is important in acute coronary syn-
drome and before an intervention procedure. To determine whether a single
low dose of iv aspirin inhibits platelet aggregation, twenty-seven healthy vol-
unteers (7 F and 20 Mj, mean age 43.5 years, were randomized double-blind
to a single iv low dose of aspirin OL-Iysine (L-ASA) equivalent to 2 mg!kg of
aspirin, high dose (H-ASA) equivalent to 10 mg!kg, or placebo (PI). Platelet ag-
gregation were performed before and 1 hand 24 h after drug administration,
in whole blood (WB) using electrical impedance and in platelet-rich plasma
(PRP) by optical light transmittance. Baseline WB platelet aggregation (Col 3
ILg/ml) was the same with L-ASA, H-ASA and PI (24 ± 5, 23 ± 3 and 24 ± 4rl
respectively) and decreased significantly more with L-ASA and H-ASA than
with PI after 1 h.(17± 6, 15± 7 and 21 ±5rl p < O.Ol)and 24h(17 ± 7, 16±
6 and 25 ± 4rl P < 0.01). Results in PRP were similar:
Inhibition of nitric oxide synthesis causes a decrease in basal diameter of dis-
tal epicardial coronary arteries in patients (pts) with normal coronary arteries
(NCA). The effects of inhibition of nitric oxide synthesis with NG-monomethyl-
L-arginine (LNMMA) in atheromatous coronary arteries was evaluated in 13
pts with chronic stable angina (aged 57 ± 7 years, 11 males) due to angio-
graphically documented coronary artery disease and in 8 pts (aged 50 ± 5
years, 4 males) with angiographically NCA. LNMMA was infused intracoro-
nary at 4,8 and 16/Lmol/min each for 4 minutes. In response to low LNMMA.
4lLmollmin, there was a significant (p < 0.05) reduction in luminal diameter
of both proximal (from 3.49 ± 0.28 to 3.35 ± 0.28 mm) and distal (from 1.33
± 0.07 to 1.23 ± 0.06 mm) segments in patients with NCA. In patients with
atheromatous arteries there was a reduction in diameter of the distal seg-
ments (from 1.44 ± 0.06 to 1.33 ± 0.07 mm) but no change occurred in the
proximal segments (from 2.95 ± 0.16to 2.89 ± 0.16 mm). In response to high
LNMMA. 16ILmol/min, there was a significant (p < 0.01) reduction in luminal
diameter of both proximallfrom 2.53 ± 0.27 to 2.33 ± 0.26 mm) and distal
(from 1.10 ± 0.06 to 0.99 ± 0.06 mm) segments in the pts with NCA. In the
pts with atheromatous arteries the distal segments decreased in diameter
(from 1.32 ± 0.07 to 1.17 ± 0.06 mm) but no change occurred in the proximal
segments (from 3.16 ± 0.12 to 3.08 ± 0.14 mm). The magnitude of the distal
vessel constriction was similar in both the patients with normal and in those
with atheromatous arteries (-9.6 ± 2.1 % and -10.9 ± 2.6% respectively, p
= NS). In conclusion in pts with chronic stable angina due to coronary artery
disease inhibition of basal nitric oxide synthesis causes distal coronary artery
vasoconstriction, but it has no effect on proximal segments.
1931-1121 A Low-dose Intravenous Aspirin, Bolus Injection,
Effectively Inhibits Platelet Aggregation
1931-1151 Phase I Studies on Inogatran, a New Selective
Thrombin Inhibitor
*p < 0.001 IANOVA test} respect to PI and the baseline values
No differences in response were observed between the two doses of aspirin
and no significant changes occurred between 1 and 24 hours in any group.
Effective inhibition of platelet aggregation is thus achieved within 1 hour
after the administration of low-dose 2 mg!kg of ivaspirin.
Ann-Catrine Teger-Nilsson, Ulf Eriksson, DaVid Gustafsson, Ruth Bylund,
Gunnar Fager, Peter Held. Astra Hassle AB, 5-431 83 M6lndal, Sweden
Inogatran is a new, synthetic, active site inhibitor of thrombin with a molecular
weight of 439 dalton. Inogatran (pINNI selectively, rapidly and competitively
binds thrombin with a Ki value of 15 nmol/l. In vitro it doubles the plasma
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H.J.F. Why, \l.B. Patel 1, PJ. Richardson, \l.R. Preedy 1. Department of Cardiology,
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Hospital, London, U. K
Hypertensive left ventricular hypertrophy(LVH) is associated with altered left
2.13±0.17
2.72 ± 0.17*
2.40 ± 0.14
2.70 ± 0.13
JLg/mg proteinJLg/g tissue JLg/mg DNA
413.0 ± 32.0 143.1 ± 48.3
525.6 ± 32.1' 183.6 ± 10.8'
452.1 ± 31.9 164.4 ± 7.2
517.8 ± 26.9 176.2 ± 8.3
LV hydroxyproline (mean ± SEM)
'p < 0.05 vs appropriate control
SHR (control)
SHR + LIS
WKY (control)
WKY + LIS
Altered Muscle Fiber Sarcomeres in Hypertrophic
Cardiomyopathy Associated with the 403Arg-+Gln
P-Myosln Heavy Chain Gene Mutation
Edward B. Lankford, Rhea Levine, Neal D. Epstein 1, Lameh Fananapazir 1. H.
Lee Sweeney. University of Pennsylvania, Phi/adelphia, PA; 1NIH, Bethesda, MD
We have shown that mutant cardiac j3-myosin is present in slow skeletal mus-
cle from patients with hypertrophic cardiomyopathy (HeM) caused by the
403Arg_Gln j3-myosin heavy chain (j3-MHC) gene mutation. Slow myofibers
with this mutation have impaired maximal isometric tension and shortening
velocity. This study examines whether ultrastructural changes account for the
altered contractile properties. Single soleus muscle fibers from 4 patients
(two unrelated kind reds) with the 403Arg_Gln mutation and 3 normal con-
trols, were chemically permeabilized, and mounted under a light microscope
at a length 10% longer than the slack length to measure sarcomeric spac-
ing. Electronmicroscopy was used to evaluate sarcomeric structure of fixed
fibers, as well as to measure the length of thick filaments obtained from elas-
tase digestion of other fibers. Although sarcomeric structure was normal, the
sarcomeric spacing was "'20% shorter compared with normal controls (1.70
versus 2.10 JLm). The isolated thick filaments were also "'20% shorter com-
pared to the normal controls: 1.25 ± 0.14 JLm (n = 248) versus 1.55 ± 0.07
JLm (n ~ 1891, P < 0.001. This reduction of thick filament length and con-
comitant decrease in myosin heads, will (1) reduce the isometric force per
cross-sectional area compared to fibers with normal length, and (2) increase
the maximal shortening velocity as there will be more sarcomeres per unit
length of muscle fiber. This observation suggests that in HCM caused by this
j3-MHC mutation, there is a pathway linking changes in the molecular motor
to alterations in sarcomeric ultrastructure.
Regression of LVH in SHR with Iisinopril treatment was associated with
significantly increased hydroxyproline per unit weight of tissue, protein and
DNA. Selective regression of cardiac proteins with lisinopril may have impor-
tant function implications.
ventricular (LV) filling; this may persist despite regression of LVH with treat-
ment. Collagen occupies about 3% of the LV mass and contributes to my-
ocardial stiffness. Collagen content may be assessed experimentally by as-
say of hydroxyproline, an amino acid virtually unique to collagen. The effects
of lisinopril treatment on LV hydroxyproline content were studied in 15 week
old spontaneously hypertensive rats (SHR) and 15 week old normotensive
Wistar Kyoto rats (WKY). Rats were treated with lisinopril (LIS) in water (5
mglkg/day) for 8 weeks. Control rats were given plain tap water. LV hydrox-
yproline content was assayed by a spectrophotometric method after sacri-
fice. LIS lowered blood pressure (BP) in SHR significantly; BP in WKY was
unaltered. LV mass was significantly greater in SHR controls than WKY con-
trols (1062 ± 40 mg vs 896 ± 9.4 mg, p < 0.01). LV mass regressed with LIS
in both SHR (1062 ± 40 vs 786 ± 18.3 mg, p < 0.001) and WKY (896 ± 9.4
vs 760 ± 33.1 mg, p < 0.01). Hydroxyproline levels were significantly higher
in treated SHR than controls: no difference was seen between treated and
control WKY.
Impaired coronary blood flow reserve and myocardial ischemia in the ab-
sence of epicardial coronary artery disease is a frequent and important patho-
physiologic feature of hypertrophic cardiomyopathy (HCM). To provide the
morphologic basis for such findings, we studied the hearts of 16 pts with
HCM (ages 11-31 yrs; mean 20) who had died suddenly. Transmural sec-
tions of ventricular septum were studied (area 5.2 ± 2 cm2) after staining with
picrosirius-red; 9 ± 2 abnormal intramural coronary arteries (IMCAs)were an-
alyzed per section. Compared to 16 structurally normal control hearts, IMCAs
in HCM had substantially greater (12-fold) collagen volume fraction in media
(2.5 ± 2-vs-0.2 ± 0.3%, p < 0.01). as well as larger outer diameter (120 ±
46-vs-82 ± 22 JLm, p < 0.01). luminal diameter (88 ± 33-vs-62 ± 19 JLm, p <
0.05), medial thickness (32 ± 20-vs-20 ± 6 JLm, p < 0.05) and also perivascular
Importance of Collagen in Myocardial Ischemia
and Remodeling of Abnormal Intramural
Coronary Arteries ("Small Vessel Disease") in
Young Patients with Hypertrophic
Cardiomyopathy and Sudden Cardiac Death
Jamshid Shirani, Ruth Pick, Barry J. Maron. Albert Einstein College of Medicine,
Bronx, NY; Minneapolis Heart InsDtute Foundation. Minneapolis, MN
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thrombin time at a concentration of 23 nmol~ and the activated partial throm-
boplastin time (APTT) at 1.1 JLmol~. Thrombin induced platelet aggregation is
inhibited at an IC50 of 17 nmol~. Inogatran was studied in healthy male hu-
man volunteers with regard to tolerability. pharmacokinetics and effects on
haemostasis. It was given intravenously as a bolus in doses from 0.002 to
1.1 JLmollkg (n = 2-4 at each dose). The highest peak plasma concentration
observed was 7 JLmol~, corresponding to an APTT prolongation of 3 times.
The drug was also given as a constant infusion over 4 h at a dose of 0.73
JLmollkg per h (n = 16) which resulted in a mean plasma concentration at
steady state of 1.9 JLmolll and an APTT prolongation of 2.3 times. Finally, it
was given as a bolus with radiolabeled compound in a total dose of 25 JLmol
(n = 16). The drug was well tolerated and without side effects with the excep-
tion of slightly increased bleeding tendency at the blood sampling site. Ino-
gatran had avolume of distribution of 0.26 mllkg and a total plasma clearance
of 6.1 mllmin per kg, resulting in a half life of about one hour. The drug was
not metabolised and it was excreted unchanged with the elimination evenly
distributed between urine and faeces. Ex vivo the thrombin time was linearly
correlated to the plasma concentration while the APTT-concentration curve
was non-linear. At the highest plasma concentrations a slight prolongation
of the capillary bleeding time was seen in some subjects. Markers of throm-
bin activity (thrombin-antithrombin complex and prothrombin fragments 1-2)
decreased during the constant infusion of the drug. There was no effect on
fibrinolysis (PAI-l and t-PA activities) or protein C. It is concluded that inoga-
tran is a safe and effective anticoagulant with favourable pharmacokinetics
for Lv. use.
We have characterised the age-related changes of contractility and j3-
adrenoceptorfunction in isolated cardiac myocytes from guinea-pigs. Pertus-
sis toxin treatment was used to determine the contribution of Gi effects to the
change in sensitivity to j3-adrenoceptor stimulation. Myocytes were isolated
from either adult animals from 2 weeks to 14 week of age, where bodyweight
increases linearly with age, or senescent ones aged between 53-65 weeks.
There was some indication of a decrease in contractility in maximum Ca2+
with age, with significant differences between a young (::04 weeks, weight
< 400 g) and aged (::.:8 weeks, weight> 600 g) group in contraction ampli-
tude (% shortening) or contraction and relaxation velocities. This decline was
continued into senescence, and ANOVA showed a significant difference be-
tween the three groups for percentage shortening (12.2 ± 0.9%, young, n =
31; 9.5 ± 0.6%, n = 28 aged; 6.7 ± 0.8%, n = 6, senescent; P = 0.005). and
contraction or relaxation velocities (P < 0.001). There was a more pronounced
decline with age for maximum contraction amplitude in isoproterenol (11.8 ±
0.7%. n = 30, young; 7.9 ± 0.5%, n = 28, aged and 5.5 ± 1.1 %, n = 6, senes-
cent; P < 0.001) and the isoproterenollCa2+ ratio was reduced (P < 002). The
EC50 value for isoproterenol was similar in young (1.7 ± 0.4 nM) and aged
(1.6 ± 0.8 nM) animals, but significantly higher in senescent (16.8 ± 6 nM) (P
< 0.05. ANOVA). Pertussis toxin treatment decreased the EC50 in all groups,
but the effect was most pronounced for senescent animals. The final EC50
values in toxin-treated cells were 0.22 ± 0.11 nM (young), 0.19 ± 0.08 nM
(aged) and 0.12 ± 0.01 nM (senescent): these were not significantly differ-
ent. A general decrease in contractility of the myocyte occurs as the animal
ages, but the effect is more pronounced for j3-adrenoceptor stimulation than
for high Ca2+, consistent with a specific lesion in the adenylate cyclase re-
lated pathway. The ability of pertussis treatment to equalise EC50 values for
isoproterenol between the groups suggests that an increase in activity of Gi
contributes to the reduced j3-adrenoceptor sensitivity in senescent animals.
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